Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia

Abstract

The standard treatment for elderly patients with AML is Ven combined with HMAs. OR21, a new oral HMA plus Ven showed synergistic antileukemia effects <i>in vitro</i> and <i>vivo</i>, suggesting that the combination of OR2100 plus Ven is a promising candidate oral therapy for AML.